Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma, Ewing × Busulfan × Clear all

Phase

Phase 1 5 Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 81 Leukemia 73 Myelodysplastic Syndromes 69 Precursor Cell Lymphoblastic Leukemia-Lymphoma 61 Lymphoma, Non-Hodgkin 53 Lymphoma 50 Multiple Myeloma 42 Hodgkin Disease 39 Leukemia, Lymphocytic, Chronic, B-Cell 38 Leukemia, Myeloid, Chronic-Phase 33 Myeloproliferative Disorders 32 Leukemia, Myeloid, Accelerated Phase 32 Congenital Abnormalities 30 Neoplasms, Plasma Cell 29 Leukemia, Myelomonocytic, Chronic 29 Lymphoma, Large B-Cell, Diffuse 28 Lymphoma, Follicular 28 Burkitt Lymphoma 28 Anemia, Refractory, with Excess of Blasts 27 Lymphoma, Mantle-Cell 26 Lymphoma, B-Cell, Marginal Zone 24 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24 Blast Crisis 24 Lymphoma, Large-Cell, Immunoblastic 23 Recurrence 22 Myelodysplastic-Myeloproliferative Diseases 21 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 20 Hematologic Neoplasms 20 Dendritic Cell Sarcoma, Interdigitating 19 Primary Myelofibrosis 17

Interventions

Cyclophosphamide 10 Temozolomide 9 Vincristine 8 Etoposide 6 Doxorubicin 6 Irinotecan 5 palbociclib 4 Topotecan 4 Melphalan 4 Magnetic Resonance Spectroscopy 4 X-Rays 3 Sirolimus 3 Phantoms, Imaging 3 Ifosfamide 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 ivosidenib 2 cixutumumab 2 cabozantinib 2 Vemurafenib 2 Trabectedin 2 Tacrolimus 2 Specimen Handling 2 Peripheral Blood Stem Cell Transplantation 2 Nuclear Medicine Department, Hospital 2 LY3023414 2 Granulocyte Colony-Stimulating Factor 2 Gemcitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727387 2022-09-19

EW-2

Italian Sarcoma Group

Phase 2 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡